Physician profile
Deanna Halbert
NPI 1013489624
$4,614.56
in general payments reported to CMS, 2019-2025
39 companies · $527 in 2025
The $527 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $323 · 2023: $1,546 · 2024: $2,219 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $780.76 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $767.48 | 2023-2025 | |
| Glaxosmithkline, LLC. | $662.40 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $253.79 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $198.44 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $141.41 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $137.62 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $132.66 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.35 | 2022 | |
| Lundbeck LLC | $120.51 | 2023-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $115.49 | 2023-2025 | Rexulti |
| Pfizer INC. | $113.88 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.09 | 2023-2025 | Xifaxan |
| Alkermes, INC. | $84.08 | 2024 | Lybalvi |
| Eisai INC. | $73.98 | 2023-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $66.56 | 2022-2023 | Xarelto |
| Axsome Therapeutics, INC. | $65.18 | 2024-2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $64.52 | 2023-2025 | Gvoke Hypopen |
| Mylan Specialty L.P. | $64.14 | 2023-2024 | Yupelri |
| Amgen INC. | $46.41 | 2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $44.19 | 2022 | |
| Lilly USA, LLC | $42.39 | 2024 | Mounjaro, Zepbound |
| Vanda Pharmaceuticals INC. | $39.03 | 2022-2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $36.77 | 2025 | Uzedy |
| Viatris Specialty LLC | $33.93 | 2025 | Yupelri |
| Dexcom, INC. | $33.15 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $32.78 | 2023-2024 | |
| Ardelyx, INC. | $31.64 | 2024 | Ibsrela |
| Corium, LLC | $28.44 | 2022-2023 | Adlarity |
| Sunovion Pharmaceuticals INC. | $26.40 | 2022 | |
| Daiichi Sankyo INC. | $19.37 | 2024 | Injectafer |
| Indivior INC. | $19.21 | 2022 | |
| Antares Pharma, INC. | $19.17 | 2023 | Nocdurna, Xyosted, Tlando |
| Gilead Sciences, INC. | $17.86 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.91 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.77 | 2023 | Edarbyclor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.38 | 2022 | |
| Philips North America LLC | $14.01 | 2024 | (Ck6) Holter |
| Sanofi-Aventis U.S. LLC | $13.41 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Halbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.